Third trial failure is end-of-the-road for Sage's neurological drug
A third trial failure this year for the same experimental neurological drug has led Sage Therapeutics to discontinue ...
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...
The Business Journals11d
Third trial failure is end-of-the-road for Sage's neurological drug
The biotech said in October that it was laying off more than 165 employees — 69 of whom work in Massachusetts ... Cambridge biotech's layoffs will cut dozens of Mass. employees Biogen ...
CNN4d
Biogen Inc.
Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
Biogen Inc.: Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Business Insider16d
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
“Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the ...
Investing25d
Biogen's SWOT analysis: stock outlook amid pipeline challenges, market shifts
Biogen, headquartered in Cambridge, Massachusetts, has established itself as a key player in the biopharmaceutical industry, focusing on innovative therapies for neurological conditions.
Yahoo Finance5d
Eisai Co., Ltd. (ESAIY)
Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...